| 3/28/2025 | CVLM | OPKO Health exchanges $152.5 million of 3.75% convertible notes for shares, cash
|
| 3/28/2024 | CV | Market Commentary: Convertibles secondary ends quarter on firm footing; Rexford adds outright; OPKO rises
|
| 1/9/2024 | CV | OPKO Health greenshoe lifts 3.75% convertibles to $230 million
|
| 1/5/2024 | CV | Market Commentary: OPKO Health convertibles price, drop below par on debut; PG&E active; Cytokinetics gains
|
| 1/5/2024 | CV | Market Commentary: Morning Commentary: OPKO Health convertible notes price, hold on trading debut
|
| 1/5/2024 | CV | New Issue: OPKO Health prices $200 million five-year convertible notes at 3.75%, up 26.83%
|
| 1/4/2024 | CV | Market Commentary: OPKO convertible offering eyed; refinancing wave begins; Cytokinetics rally continues
|
| 1/4/2024 | CV | Market Commentary: Morning Commentary: OPKO Health convertible offering eyed; refinancing wave begins
|
| 1/3/2024 | CV | Market Commentary: OPKO reopens primary; high-grade convertibles eyed; PG&E active; MicroStrategy lower
|
| 1/3/2024 | CV | OPKO Health talks $200 million five-year convertible notes to yield 3.25%-3.75%, up 25%-30%
|
| 5/7/2021 | CVLM | OPKO to exchange $55.42 million 4.5% convertibles for shares
|
| 7/21/2020 | CV | Market Commentary: LendingTree convertible offering oversubscribed; OPKO Health skyrockets; Coupa active
|
| 2/6/2019 | CV | Market Commentary: Semiconductor convertibles eyed; Zendesk, Microchip active on earnings; OPKO improves
|
| 2/6/2019 | CV | Market Commentary: Morning Commentary: Zendesk active on earnings beat, contracts; OPKO Health up outright
|
| 2/5/2019 | CV | Market Commentary: OPKO Health’s new convertible notes hit the market, trade at par; Illumina active
|
| 2/5/2019 | CV | Market Commentary: Morning Commentary: OPKO Health’s new convertible notes hit the market, trade at par
|
| 2/5/2019 | CV | New Issue: OPKO prices $200 million six-year convertibles to yield 4.5%, up 20%
|
| 2/4/2019 | CV | Market Commentary: OPKO on tap; Micron contracts on call news; Aurora Cannabis expands; Weatherford better
|
| 2/4/2019 | CV | OPKO Health plans to price $200 million six-year convertible notes to yield 4.5%, up 20%
|
| 1/8/2019 | CVLM | OPKO Health offers to repurchase all or some 3% convertible notes
|
| 10/3/2016 | CV | OPKO stock triggers conversion option for 3% notes through December
|
| 7/1/2016 | CV | OPKO stock triggers conversion option for 3% notes through September
|
| 4/6/2016 | CV | OPKO Health’s 3% notes due 2033 to stay convertible through June 30
|
| 1/5/2016 | CV | OPKO Health’s 3% notes due 2033 to stay convertible through March 31
|
| 10/1/2015 | CV | OPKO Health’s 3% notes due 2033 to stay convertible through Dec. 31
|
| 7/1/2015 | CV | OPKO Health’s 3% notes due 2033 to stay convertible through Sept. 30
|
| 4/1/2015 | CV | OPKO Health holders may convert 3% notes due 2033 through June 30
|
| 3/30/2015 | CVLM | OPKO Health issues stock, cash for $36.4 million 3% convertibles
|
| 6/20/2014 | CVLM | OPKO Health to issue shares, cash for $70.4 million 3% convertibles
|
| 8/30/2013 | CV | OPKO Health holders may convert 3% notes due 2033 though next Friday
|
| 1/25/2013 | CV | New Issue: OPKO Health prices upsized $175 million 20-year convertibles to yield 3%, up 20%
|
| 1/25/2013 | CV | Market Commentary: Market sees $1 billion in four deals; Auxilium adds on hedge; Molycorp surges with shares
|
| 1/24/2013 | CV | Market Commentary: New KB Home trades flat on hedge on debut; Auxilium offering upsized, talked terms revised
|
| 1/23/2013 | CV | OPKO Health to price $150 million 20-year convertibles to yield 2.75%-3.25%, up 17.5%-22.5%
|
| 1/23/2013 | CV | Market Commentary: Planned KB Home adds in gray; newer Theravance still weak; Molycorp, OPKO, Auxilium on tap
|
